Eli Lilly's Strong 2023 Financial Results and Weight-Loss Drug Demand Outlook
TL;DR Summary
Eli Lilly's strong fourth-quarter results and 2024 sales guidance exceeding Wall Street's expectations have led to an increase in the stock's price target by $120, reinforcing its position as the world's most valuable drugmaker.
- We're not joining the sellers of Eli Lilly after its earnings results CNBC
- Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance | Eli Lilly and Company Investors | Eli Lilly and Company
- Eli Lilly CFO: Weight-loss drug demand will outstrip GLP-1 supply through 2024 Yahoo Finance
- Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue CNBC
- Lilly's new weight-loss shot drives sales beat Detroit News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
43%
60 → 34 words
Want the full story? Read the original article
Read on CNBC